Re: Genomic Classifier Identifies Men with Adverse Pathology after Radical Prostatectomy Who Benefit from Adjuvant Radiation Therapy

European Urology

Volumn 69, Issue 3, 2016, Pages 539-540

  Chan, Jason ^a   Roach, Mack ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE;

ANDROGEN DEPRIVATION THERAPY; BONE SCINTISCANNING; CANCER RADIOTHERAPY; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; GENOMIC CLASSIFIER SCORE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NOTE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; ADJUVANT RADIOTHERAPY; GENETICS; PROCEDURES; PROSTATIC NEOPLASMS;

HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 84973527177     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.12.026     Document Type: Note

References (4)

1. A.J. Stephenson, and et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041
2. M.R. Cooperberg, and et al. The CAPRA-S score Cancer 117 2011 5039 5046
3. C.R. Pound, and et al. Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
4. P.L. Nguyen, and et al. Impact of a genomic classifier of metastatic risk on postprostatectomy treatment recommendations by radiation oncologists and urologists Urology 86 2015 35 40